206 related articles for article (PubMed ID: 35269532)
21. Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Oki S; Sone K; Oda K; Hamamoto R; Ikemura M; Maeda D; Takeuchi M; Tanikawa M; Mori-Uchino M; Nagasaka K; Miyasaka A; Kashiyama T; Ikeda Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Fukayama M; Osuga Y; Fujii T
Oncotarget; 2017 Jun; 8(25):40402-40411. PubMed ID: 28418882
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells.
Konno Y; Dong P; Xiong Y; Suzuki F; Lu J; Cai M; Watari H; Mitamura T; Hosaka M; Hanley SJ; Kudo M; Sakuragi N
Oncotarget; 2014 Aug; 5(15):6049-62. PubMed ID: 25153722
[TBL] [Abstract][Full Text] [Related]
23. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
24. Hsa_circ_0006232 promotes laryngeal squamous cell cancer progression through FUS-mediated EZH2 stabilization.
Wu T; Wang G; Zeng X; Sun Z; Li S; Wang W; Yu B
Cell Cycle; 2021 Sep; 20(18):1799-1811. PubMed ID: 34437823
[TBL] [Abstract][Full Text] [Related]
25. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
26. TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer.
Gui T; Liu M; Yao B; Jiang H; Yang D; Li Q; Zeng X; Wang Y; Cao J; Deng Y; Li X; Xu P; Zhou L; Li D; Wang Z; Zen K; Huang DCS; Chen B; Wan G; Zhao Q
Cell Death Differ; 2021 Dec; 28(12):3316-3328. PubMed ID: 34175897
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
28. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
[TBL] [Abstract][Full Text] [Related]
29. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
[TBL] [Abstract][Full Text] [Related]
31. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice.
Daikoku T; Hirota Y; Tranguch S; Joshi AR; DeMayo FJ; Lydon JP; Ellenson LH; Dey SK
Cancer Res; 2008 Jul; 68(14):5619-27. PubMed ID: 18632614
[TBL] [Abstract][Full Text] [Related]
32. Regulatory roles of alternative splicing at Ezh2 gene in mouse oocytes.
Guo SM; Liu XP; Tian Q; Fei CF; Zhang YR; Li ZM; Yin Y; He X; Zhou LQ
Reprod Biol Endocrinol; 2022 Jul; 20(1):99. PubMed ID: 35791029
[TBL] [Abstract][Full Text] [Related]
33. Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma.
Joshi A; Ellenson LH
Exp Cell Res; 2011 Jul; 317(11):1580-9. PubMed ID: 21397598
[TBL] [Abstract][Full Text] [Related]
34. [Expression of enhancer of zesle homolog 2 and phosphatase and tension homolog and its clinicopathological significance in benign and malignant lesion of gallbladder].
Liu DC; Yang ZL; Yang LP
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul; 33(7):618-22. PubMed ID: 18667776
[TBL] [Abstract][Full Text] [Related]
35. Mice lacking uterine enhancer of zeste homolog 2 have transcriptomic changes associated with uterine epithelial proliferation.
Mesa AM; Mao J; Nanjappa MK; Medrano TI; Tevosian S; Yu F; Kinkade J; Lyu Z; Liu Y; Joshi T; Wang D; Rosenfeld CS; Cooke PS
Physiol Genomics; 2020 Feb; 52(2):81-95. PubMed ID: 31841397
[TBL] [Abstract][Full Text] [Related]
36. Steroid hormone intervenes in the endometrial tumorigenesis of pten ablation.
Kim HI; Kim TH; Lim JM; Jeong JW
J Cancer Prev; 2013 Dec; 18(4):313-21. PubMed ID: 25337560
[TBL] [Abstract][Full Text] [Related]
37. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
38. O-linked N-acetylglucosaminyltransferase OGT inhibits diabetic nephropathy by stabilizing histone methyltransferases EZH2 via the HES1/PTEN axis.
Fang N; Li P
Life Sci; 2021 Jun; 274():119226. PubMed ID: 33609540
[TBL] [Abstract][Full Text] [Related]
39. Enhancer of Zeste Homolog 2 in Colorectal Cancer Development and Progression.
Bremer SCB; Conradi LC; Mechie NC; Amanzada A; Mavropoulou E; Kitz J; Ghadimi M; Ellenrieder V; Ströbel P; Hessmann E; Gaedcke J; Bohnenberger H
Digestion; 2021; 102(2):227-235. PubMed ID: 31694013
[TBL] [Abstract][Full Text] [Related]
40. Roles of enhancer of zeste homolog 2: from skeletal muscle differentiation to rhabdomyosarcoma carcinogenesis.
Marchesi I; Giordano A; Bagella L
Cell Cycle; 2014; 13(4):516-27. PubMed ID: 24496329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
